 |
| Anno II | Numero 11 | Marzo 2017 |
| Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis |
| Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported in this rare melanoma subtype. Data were pooled from 889 patients who received nivolumab monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665 … |
| Continua a leggere |
| Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone |
| There is a growing body of evidence supporting the synergistic roles of radiotherapy and immunotherapy in the treatment of malignancy. Published case studies of the abscopal effect have been reported with the use of ipilimumab and radiotherapy in metastatic melanoma, but evidence supporting the routine use of this combination of therapy is limited. We conducted a retrospective analysis to evaluate patients treated with ipilimumab for advanced melanoma at a single … |
| Continua a leggere |
| The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma |
| Body composition is an important predictor of drug toxicity and outcome. Ipilimumab (Ipi), a monoclonal antibody used to treat metastatic melanoma, has specific toxicities. No validated biomarkers that predict Ipi toxicity and efficacy exist. Also, the impact of Ipi on body composition has not been established. Patients with metastatic melanoma treated with Ipi between 2009 and 2015 were included. Body composition was assessed by computed tomography at baseline and after four cycles … |
| Continua a leggere |
| A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma |
| Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label, single institution, phase Ib study to assess the safety and tolerability of using these two agents in combination. Study treatment consisted of ipilimumab given every 3 weeks, for a total of four infusions, concurrent with peginterferon alfa-2b administered … |
| Continua a leggere |
| Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab |
| The Common Terminology Criteria for Adverse Events (CTCAE) were developed to document the adverse effects of chemotherapy but are now also used to document immune-related adverse events (irAE). Characterization of irAE by the CTCAE has implications for determining dose-limiting toxicity (DLT) and, consequently, the recommended phase II dose (RP2D) of investigational agents. In the phase I trial of nivolumab + ipilimumab, an asymptomatic increase in lipase … |
| Continua a leggere |
| Appuntamenti AIOM |
Workshop: Il Governo dell’Innovazione Farmaceutica Modelli di Gestione Sostenibile dei Farmaci Oncologici Innovativi ad Alto Costo |
| Milano, 10 marzo 2017 |
| GOIRC: Sostenibilità in Oncologia nella Pratica Clinica e nella Ricerca |
| Firenze, 10 marzo 2017 |
| Melanoma.net 2017 |
| Napoli, 15 – 16 marzo 2017 |
| Master Course IMI Management del paziente con melanoma, dalla ricerca alla terapia |
| Cagliari, 17 – 18 marzo 2017 |
| La Professione tra Innovazione e Politiche della Salute per lo Stato e il Mercato FarmacistaPiù IV Edizione |
| Milano, 17 – 19 marzo 2017 |
| pd-L1: un riferimento emergente nell’immuno-oncologia |
| Bari, 18 marzo 2017 Napoli, 23 marzo 2017 Aci Castello (CT), 25 marzo 2017 Parma, 12 aprile 2017 |
| La Presa in Carico Globale del Paziente Oncologico: tra Appropriatezza, Innovazione e Sostenibilità |
| Patrocinio concesso dalla Sezione Regionale AIOM Lombardia Pavia, 24 marzo 2017 |
| La Sostenibilità Futura del Servizio Sanitario: Possibili Strategie e Sinergie |
| Firenze, 31 marzo 2017 |
| La gestione del rischio in oncologia tra sicurezza e qualità Conferenza Nazionale CIPOMO |
| Ascoli Piceno, 31 marzo – 1 aprile 2017 |
| Workshop Immuno-Oncologia |
| Padova, 7 – 8 aprile 2017 |
| DOMINO Workshop DecisiOn Making IN Oncology |
| Milano, 12 aprile 2017 |
| FOCUS ON: Terapie Innovative in Oncologia |
| Pistoia, 12 maggio 2017 |
| Master Course IMI Management del paziente con melanoma, dalla ricerca alla terapia |
| Recanati (MC), 12 – 13 maggio 2017 |
| Innovazione e Nanomedicina al Servizio del Paziente Oncologico Anziano |
| Catania, 18 maggio 2017 |
| DOMINO Workshop DecisiOn Making IN Oncology |
| Roma, 22 maggio 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo incondizionato di  |